Three-drug combination remodels immune environment in gastric cancer
A triplet combination therapy can remodel the tumor microenvironment in patients with advanced gastric cancer and shows a promising safety profile, according to results from a new phase 2 clinical trial.
Read original article on The Medical News →Related news
-
Modified zinc finger scaffold suppresses microglial activation in mouse brain
United Kingdom
-
New tool identifies older adults at risk of delirium and falls from anticholinergic medications
United Kingdom
-
Tau spreads more rapidly in early-onset Alzheimer's disease
United Kingdom
-
Brain scans reveal clues to Alzheimer's risk years before memory loss begins
United Kingdom
-
Simple text reminders could help close London's bowel cancer screening gap
United Kingdom
-
Teen chlamydia and gonorrhea screening climbs to 75% after primary care changes
United Kingdom
-
Targeting brain protein may help treat MEF2C-related neurological disorders
United Kingdom
-
ACS Emergency General Surgery Verification associated with fewer deaths and shorter stays
United Kingdom